- Overview
- Key stats
- Stock price
- Financial performance
- Growth
- Valuations
- Efficiency
- Dividends
- Financial health
- Stocks
- Healthcare
- NASDAQ: MRNA
Price (delayed)
$27.61
Market cap
$10.68B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.73
Enterprise value
$9.76B
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...
Highlights
The gross margin has soared by 142% YoY
The net income has grown by 44% YoY and by 6% from the previous quarter
MRNA's gross profit is up by 49% YoY but it is down by 3% from the previous quarter
MRNA's revenue is down by 38% year-on-year
The equity is down by 21% YoY and by 8% QoQ
Key stats
What are the main financial stats of MRNA
MarketValuationsEarnings
Shares outstanding
386.74M
Market cap
$10.68B
Enterprise value
$9.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.06
Price to sales (P/S)
3.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.07
Revenue
$3.18B
Gross profit
$1.72B
Operating income
-$3.73B
Net income
-$3.36B
EBIT
-$3.41B
EBITDA
-$3.21B
Free cash flow
-$4.03B
Per shareBalance sheetLiquidity
EPS
-$8.73
EPS diluted
-$8.73
Free cash flow per share
-$10.45
Book value per share
$26.09
Revenue per share
$8.23
TBVPS
$32.91
Total assets
$12.7B
Total liabilities
$2.64B
Debt
$702M
Equity
$10.07B
Working capital
$5.16B
Debt to equity
0.07
Current ratio
4.22
Quick ratio
3.77
Net debt/EBITDA
0.29
MarginsEfficiencyDividend
EBITDA margin
-101.2%
Gross margin
54.1%
Net margin
-105.7%
Operating margin
-117.4%
Return on assets
-23%
Return on equity
-30.1%
Return on invested capital
-29.5%
Return on capital employed
-30.7%
Return on sales
-107.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
2.15%
1 week
1.43%
1 month
-0.4%
1 year
-78.02%
YTD
-33.6%
QTD
-2.61%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$3.18B
Gross profit
$1.72B
Operating income
-$3.73B
Net income
-$3.36B
Gross margin
54.1%
Net margin
-105.7%
MRNA financials
The gross margin has soared by 142% YoY
MRNA's gross profit is up by 49% YoY but it is down by 3% from the previous quarter
The net income has grown by 44% YoY and by 6% from the previous quarter
MRNA's revenue is down by 38% year-on-year
Price vs fundamentals
Earnings waterfall
Growth
What is Moderna's growth rate over time
MRNA growth chart
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
1.06
P/S
3.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.07
Valuation vs average
Price to earnings (P/E)
The company's EPS rose by 44% YoY and by 6% QoQ
Price to book (P/B)
MRNA's P/B is 83% below its 5-year quarterly average of 6.1 and 52% below its last 4 quarters average of 2.2
The equity is down by 21% YoY and by 8% QoQ
Price to sales (P/S)
The stock's P/S is 87% below its 5-year quarterly average of 25.3 and 40% below its last 4 quarters average of 5.6
MRNA's revenue is down by 38% year-on-year
Efficiency
How efficient is Moderna business performance
MRNA's return on equity is up by 28% year-on-year
Moderna's ROA has increased by 26% YoY
The company's return on sales fell by 15% YoY but it rose by 3.9% QoQ
The ROIC has grown by 13% YoY
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
Assets vs liabilities
Moderna's total liabilities has decreased by 33% YoY and by 19% QoQ
Moderna's total assets has decreased by 24% YoY and by 10% from the previous quarter
Debt vs equity
The debt is 93% smaller than the equity
The debt has declined by 42% year-on-year
The company's debt to equity fell by 22% YoY
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.